Mitochondrial protein acetylation correlates with a decrease in sirtuin 3 levels. by Mercedes García-Roche (6459200)

Homozygous deletion of <i>ERG251</i> leads to increased sensitivity to cell membrane and osmotic stress but decreased sensitivity to oxidative stress. by Xin Zhou (54275)

Wnt signaling decreases the recruitment of RAB8a to basal bodies. by Cheng Yuan (160315)

The TSS diversity of a gene generally decreases with the gene expression level. by Chuan Xu (293667)

EtOH decreased ΔΨm in a subset of esophageal keratinocytes. by Prasanna M. Chandramouleeswaran (3176268)

Effects of FE and RUD wrist postures on the mean shape signature distance from the template within each quartile. by Drew A. Anderson (14197446)

Subjects:

Illustration of the predicted mean (n = 10) twist along the carpal tunnel in neutral and with combined FE and RUD postures. by Drew A. Anderson (14197446)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects: